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Obesity-related breast cancer is an important threat that affects especially
post-menopausal women. The link between obesity and breast cancer seems to
be relying on the microenvironment generated at adipose tissue level, which includes
inflammatory cytokines. In addition, its association with systemic endocrine changes,
including hyperinsulinemia, increased estrogens levels, and hyperleptinemia may
be key factors for tumor development. These factors may promote tumor initiation,
tumor primary growth, tissue invasion, and metastatic progression. Although the
relationship between obesity and breast cancer is already established, the different
pathophysiological mechanisms involved are not clear. Obesity-related insulin resistance
is a well-known risk factor for breast cancer development in post-menopausal women.
However, the role of inflammation and other adipokines, especially leptin, is less studied.
Leptin, like insulin, appears to be a growth factor for breast cancer cells. There exists a
link between leptin and metabolism of estrogens and between leptin and other factors
in a more complex network. As a result, obesity-associated hyperleptinemia has been
suggested as an important mediator in the pathophysiology of breast cancer. On the
other hand, recent data on the paradoxical effect of obesity on cancer immunotherapy
efficacy has brought some controversy, since the proinflammatory effect of leptin may
help the effect of immune checkpoint inhibitors. Therefore, a better knowledge of the
molecular mechanisms that mediate leptin action may be helpful to understand the
underlying processes which link obesity to breast cancer in post-menopausal women,
as well as the possible role of leptin in the response to immunotherapy in obese patients.
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In western countries, the incidence of breast cancer has increased more than 30% in the last 25
years. Even though this is attributed in part to changes in reproductive patterns and improved
detection methods, this increase may also reflect the increasing prevalence of obesity and physical
inactivity in the population (1).
Overweight and obesity seem to be inversely related to the incidence of breast cancer in
pre-menopausal women. However, in the development of post-menopausal breast cancer, as
happens with other tumors, obesity has been considered a major risk factor. A meta-analysis of
prospective observational studies revealed this relationship, concluding that there is an increased
risk of 12% of breast cancer in post-menopausal women for each increase of 5 kg/m2 in body mass
index (BMI) (2).
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Increased adiposity has been correlated with large tumor size,
tumor node positivity and poor prognosis of breast cancer (3).
Obesity affects many hallmarks of cancer, including genomic
instability, tissue metabolic changes, altered extracellular matrix
properties, dysregulation of cell death, immune system, and
angiogenesis (4).
The aim of this article is to review the current literature
to better understand the relationship between obesity and
breast cancer and to compile the known molecular mechanisms
underlying this association. Finally, we will summarize new data
regarding the obesity paradox based on the beneficial effect
of overweight on the results of immunotherapy of cancer and
discuss the possible role of leptin.
MAIN MECHANISMS INVOLVED IN OBESE
ASSOCIATED BREAST CANCER
Several mechanisms closely related to each other have been
proposed to explain specifically the association between breast
cancer and obesity, including chronic subclinical inflammation,
sex hormone deregulation, insulin/IGF-1 pathways, and the
secretion of different adipokines, where leptin plays a key
role (Figure 1).
Chronic Inflammation
It has been demonstrated that adipose chronic inflammation
increases the survival and proliferation of cancer cells, promotes
angiogenesis, metastatic spread, alters antitumor immune
responses, and interfere with hormonal or chemotherapeutic
treatments having a role in cancer prognosis (5, 6). At the
tumor site, the presence of histological focal inflammatory points
known as crown-like structures (CLS) and the proximity of
adipose stromal cells, lead to the generation of a proinflammatory
microenvironment. Thus, there are increased levels of infiltrated
M1 macrophages, cytokines and pro-inflammatory mediators,
such as cyclooxygenase-2 (COX-2), TNF-α, IL-6, monocyte
chemoattractant protein-1 (MCP-1), and interleukin (IL)-1β (7)
around the tumor site. Several inflammatory mediators produced
by inflammatory cells also regulate leptin expression in this
context and promote the development of chronic inflammation
(8). The overall leptin action in the immune system is to
activate proinflammatory cells, promote T-helper 1 responses,
and mediate the production of the other proinflammatory
cytokines (9, 10). Inflamed adipose tissue also induces neutrophil
differentiation, leading to increased neutrophilia that seems to
be mediated by high levels of GM-CSF. This is also responsible
for the recruitment of several immunosuppressive cells in
the adipose microenvironment, namely T-regulatory (T-reg)
cells, myeloid-derived suppressor cells (MDSCs), and tumor-
associated macrophages (TAMs) (11, 12).
Sex Hormone Deregulation
After menopause, adipose tissue becomes the main producer of
estrogens through the enzymatic conversion of androstenedione
to estrone, carried out by aromatase from stromal cells. In obese
women, aromatase activity is elevated resulting in increased
estrogen production and in relatively high plasma levels. This is
associated with an increase in the risk of breast cancer and with
the worst prognosis observed in this population (13, 14).
Factors produced during inflammation and the paracrine loop
that is established between macrophages and adipose stromal
cells may induce the aromatase enzyme, with the consequent
stimulation of ER-positive breast cancer epithelial cell growth
through locally produced estrogens. Thus, there seems to be a
strong correlation among obesity, inflammation, and hormone-
receptor positive cancer (15, 16). This association is in line with
the major role that estrogens synthesized by stromal adipose
tissue have in the pathogenesis of these tumors.
Other factors that are related to the deregulation of sex
hormones in this context are the adipose tissue containing 17β-
hydroxysteroid dehydrogenase, which is responsible for the more
biologically potent conversion of estrone to estradiol, as well
as the decrease of the sex hormone binding globulin (SHBG)
levels, which in turn, increases the level of biologically available
estradiol (13).
Insulin
As part of the adipose metabolic alterations, insulin is another
obesity-related factor that induces the activity of adipose
aromatase, while directly stimulating the growth and invasion
of breast cancer cells (16–18). The coexistence of deregulated
insulin signaling in obesity has been well-known for decades.
BMI correlates directly with circulating insulin and insulin-like
growth factor-1 (IGF-1). High levels of insulin, as a consequence
of insulin resistance in obese women, are also associated with
an increased risk of post-menopausal breast cancer as well as
an increased risk of cancer recurrence and mortality (1, 13).
Hyperinsulinemia contributes to the development of cancer due
to the direct effects exerted by insulin promoting growth, and
indirectly, due to the decrease of circulating levels of IGF-1
binding proteins (IGFBP3), which increases the bioavailability
of this growth factor. High level of IGF-1 has been associated
with increased risk of breast cancer in both pre-menopausal
and post-menopausal women (19). Also hyperglycemia seems to
increase the risk of breast cancer in pre-malignant cells and to
enhance cancer progression in malignant epithelial cells through
leptin/IGF1 signaling (20).
The binding of insulin or IGF-1 to its specific receptors
activates several growth promoting signaling pathways, including
MAPK and PI3K/Akt/mTOR. Additionally, insulin prevents
apoptosis by inducing increased expression of the anti-apoptotic
proteins Bcl-2 and Bcl-XL, and the concomitant suppression of
the pro-apoptotic protein Bax. Increased signaling by insulin,
positively regulates vascular endothelial growth factor (VEGF)
and the hypoxia-inducible factor 1α (HIF-1α) to promote tumor
angiogenesis, proliferation of endothelial cells, and the formation
of blood vessels. All of them, mechanisms involved in the
development, progression, and invasion of breast cancer (21, 22).
Adipokines
Aberrant adipokine and cytokine signaling represents one of the
key features of obese metabolism and the physiopathology of
obesity-related diseases. Adipocytes in obese individuals produce
endocrine, inflammatory and angiogenic factors to affect adjacent
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FIGURE 1 | Breast cancer and obesity. The picture summarizes the mechanisms that connect obesity or excess of adipose tissue with the development of
breast cancer.
breast cancer cells. Traditionally, the two most important
adipokines associated with the development of breast cancer
related to obesity are leptin, which will be extensively reviewed
below, and adiponectin (23). Adiponectin exerts a negative
regulatory function in obesity-related breast carcinogenesis.
Hence, low levels of adiponectin, characteristic of obesity, are
associated with increased proliferative activity, resulting in an
increased risk of developing cancer. In addition, low serum
adiponectin levels are also associated with a larger tumor size
and a poorer prognosis of breast cancer (24). Based on the
antagonistic impact on the risk of breast cancer, some authors
have proposed that the adiponectin/leptin ratio may be more
useful than the individual levels of adipokines for assessing
the risk profile of breast cancer (25). Adiponectin increases
the expression and activity of the physiological inhibitor of
leptin signaling protein tyrosine phosphatase 1B (PTP1B) (26)
and activates adenosinemonophosphate-activated protein kinase
(AMPK), which has a variety of cellular effects including
induction of cell cycle arrest and inhibition of mammalian target
of rapamycin (mTOR) activity. More recently, adiponectin has
been related to the induction of autophagic cell death in breast
cancer (27).
LEPTIN AND BREAST CANCER
One of the pathophysiological factors of breast cancer in obesity
is hyperleptinemia. Leptin is considered both hormone and
adipokine and it is produced and secreted into circulation
mainly by adipose tissue. It is also synthesized and secreted
by placenta and in small amounts, by the mucosa of the
gastric fundus, skeletal muscle, brain, bone marrow, lymphoid
tissues, immune cells, ovaries, endometrium during embryo
implantation, and both normal and malignant tissue of the
breast (28, 29).
Both leptin secretion and leptin circulation present
fluctuations that follow a circadian rhythm and they also
change with nutritional status. Circulating levels of leptin
communicate the state of energy storage to the brain. These
levels reflect the amount of existing adipose tissue, increasing in
proportion to the BMI. In addition, it has been demonstrated
that serum leptin levels are higher in women compared to men,
even after correction of body weight. This could be explained
by subcutaneous synthesis and estrogens and androgens
regulation (30).
The main function of leptin is the maintenance of energy
homeostasis, participating in the anorexigenic pathway through
a central feedback mechanism at the level of the hypothalamus.
In this way, it controls the growth of adipose tissue through
intermediate hormonal mechanisms that regulate food intake.
In addition to this main function, it is known that leptin
has effects on fetal development, reproduction, lactation, bone
development, hematopoiesis, immune response, angiogenesis,
and the proliferation of many different cell types, including cells
of breast tissue (25, 29, 31). One of the peripheral functions
of leptin is a regulatory role in the interplay between energy
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metabolism and the immune system, in part responsible for the
inflammatory state associated to obesity (32).
Elevated leptin levels has been linked to breast cancer
aggressiveness and bad prognosis in epidemiological studies
(33, 34). Moreover, this hormone/cytokine has been recently
suggested as a biomarker that could be associated with type,
grade, stage, lymph node involvement, hormone receptors, and
recurrence in breast cancer based on its immunohistochemical
staining (35).
Leptin signaling has been shown to regulate various
important molecules involved in proliferation, adhesion,
invasion, migration, inflammation, and angiogenesis, as it has
been demonstrated in breast carcinogenesis with the regulation
of the expression of cyclin D1, p53, survivin, IL1, E-Cadherin,
vascular endothelial growth factor and its receptor type 2, and
several tissue factors (36–44).
In breast cancer, leptin has been proposed to have a role
at different levels (45, 46). At a carcinogenic level, it has been
suggested to act as a direct potential activator of short term ROS
production in human epithelial mammary cells (47), although
other studies previously showed that chronic leptin treatment
decreases ROS levels and oxidative stress in MCF-7 cells (48).
According to the trophic function of leptin, demonstrated also in
MCF7 cells (49), it seems to regulate metabolic reprogramming
to promote cellular growth (50). However, the pro-carcinogenic
effect of leptin in breast cancer results not only from an enhanced
activity of signaling pathways involved in the proliferation
process, but also from a probable down-regulation of the
apoptotic response (51). Thus, a cardinal role of leptin in
autophagy and suppression of apoptosis in cancer cells has been
proposed as well (52). Additionally, leptin has been considered
as a mediator of tumor-stromal interactions (53), where it
seems to participate in the crosstalk between breast cancer cells
and tumor-associated macrophages M2 by stimulating IL-18
and IL-8 production to promote tumor growth and metastasis
(54) (Figure 2). More recently, leptin has been proposed to
promote cancer stem cells (CSC) enrichment and epithelial-to-
mesenchymal transition (EMT) phenotype by upregulating the
expression of multiple CSC/EMT–related genes (55).
Regarding regulation of leptin expression in breast
carcinogenesis, it is remarkable that hyperinsulinemia induces
breast cancer progression also through leptin-expression-
dependent mechanisms (56). One of the mechanisms of leptin
overexpression in breast tumors seems to involve HIF-1α, a
component of HIF transcriptional factor that can be upregulated
by hypoxia and hyperinsulinemia (57). Moreover, a recent study
FIGURE 2 | Beneficial effect of obesity on the effects of immunotherapy of cancer. Obesity is commonly associated with an “inflammatory” state with increased
pro-inflammatory immune cells as well as increased levels of inflammatory cytokines, such as leptin. In this environment, leptin could promote the switch toward T
helper 1 (Th1) cell immune responses and could act as a negative signal for the expansion of human regulatory T cells (Treg). Low BMI may be useful for the immune
escape, whereas high BMI and obesity, via inflammatory adipokines, such as leptin may help to the immunotherapy of cancer, providing support to the increased
immune response of the host to the tumor.
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has demonstrated that obesity reduces the level of the tumor
suppressor p16INK4A protein in breast adipocytes, which in
turn seems to upregulate leptin expression at mRNA level to
promote also procarcinogenic processes (58). On the other
hand, other studies have suggested a role for the protein
BMP9 as a negative regulator of leptin expression in breast
cancer cells (59).
Leptin Receptor
The mechanism of leptin action starts with the activation of
its transmembrane receptor, called Ob-R or LEPR, which has a
helical structure and is related to class I cytokine receptors. LEPR
is present in tissues such as pancreas, placenta, adrenal glands,
stomach, hematopoietic cells, liver, heart, lung as well as breast
cells (30).
These receptors lack autophosphorylation capabilities so they
need auxiliary kinases for their activation. The Ob-R/LEPR
receptor has 6 isoforms resulting from different alternative
splicing of the gene: there are four of themwith short cytoplasmic
domains (Ob-Ra, Ob-Rc, Ob-Rd, and Ob-Rf), a long form Ob-
Rb and a soluble form Ob-Re, whose main function is to control
serum leptin levels. These six isoforms share an extracellular
domain of common leptin binding capacity, but they differ
in their intracellular domains. Ob-Ra, Ob-Rb, Ob-Rc, Ob-Rd,
and Ob-Rf receptors are transmembrane receptors that contain
the domain called Box1, required for the binding of janus
kinase 2 (JAK2), to activate the PI3K and MAPK signaling
pathways. However, only Ob-Rb has a coupling site (box 2)
essential for the activation of the JAK-STAT pathway and it is
the only leptin receptor that has a potentially phosphorylated
intracellular domain in three different tyrosine residues (985,
1,077, and 1,138). Tyrosine residue 1,138 anchors to STAT3,
while residue 985 anchors to SHP2 and also to SOCS3,
which negatively regulates leptin signaling (60). Through JAK2
activation, this long form of the leptin receptor is responsible for
the main effects of leptin on the energy homeostasis and other
neuroendocrine functions.
Leptin and LEPR are overexpressed in breast cancer as
compared to non-cancer mammary epithelium (61). Moreover,
immunohistochemical studies have shown overexpression of
leptin receptors in breast cancer tissue samples of different stages,
from primary to metastatic (62). In this sense, LEPR was also
demonstrated to be necessary for maintaining CSC metastatic
properties (63). This demonstrated that leptin can influence
breast cancer cells not only by endocrine and/or paracrine
actions, but also through autocrine pathways. High levels of
leptin and overexpression of its receptors in obese women can
lead to an increase in signaling, key in the development of breast
cancer (29).
Major Leptin Signaling Pathways in Breast
Cancer
Through binding to its receptor, leptin stimulates a cascade
of signaling events and elicit subsequent cellular effects
(Figure 3). Leptin induces canonical (JAK2/STATs; MAPK/ERK
1/2, PI3K/AKT) and non-canonical signaling pathways (PKC,
JNK, p38 MAPK, and AMPK) in diverse cellular types (64, 65).
Some multifunctional adaptor proteins and enzymes have
been proposed to have a role participating in the activation of
these signaling pathways. Despite the underlying mechanisms
still remain poorly understood, proteins that have been
previously related to cancer as well as to insulin signaling, such
as APPL1 or Sam68, seem to positively mediate leptin induced
phosphorylation of the main pathways activated by this hormone
in breast cancer (66, 67).
JAK-STAT Pathway
The JAK/STAT signaling pathway participates in the regulation
of proliferation, survival, mobility, and cellular apoptosis in
different tissues and organs (68). It has been shown that leptin
promotes the development and progression of breast cancer
neoplastic cells by activating the JAK2/STAT3 pathway. After
the binding of leptin to its receptor, activated JAK2 kinase
phosphorylates the tyrosine 1,138 residue in the cytoplasmic
domain of the leptin receptor. This provides an anchoring site for
the STAT3 protein, which is recruited through its SH2 domain.
Once STAT3 is bound to the receptor, it is phosphorylated
by JAK2 and STAT3 proteins dimerize, thus allowing their
translocation to the nucleus. There, they act as activators of
the transcription of various genes, such as c-myc, cyclin D1,
p21/waf1, c-jun, junB, erg-1, and Bcl-2, all of them involved in
cell growth and proliferation (69). In addition, STAT3 dimers
can activate the transcription of genes such as SOCS3, which
modulate the effects of leptin on cells, as well as VEGF, involved
in angiogenesis.
Signaling via JAK2/STAT3 is a critical regulatory component
in carcinogenesis in breast cancer related to obesity (70). It
has been demonstrated that leptin regulates the cell cycle and
increases breast cancer cell growth by inducing cyclin D1
expression via STAT3 activation (38). A different proliferative
effect of leptin in breast cancer cells involves the leptin mediated
upregulation of human telomerase reverse transcriptase (hTERT)
activity and expression in a dose-dependent fashion also
involving STAT3 phosphorylation (71). Moreover, enhanced
STAT3 signaling has been demonstrated to lead to altered
expression in the key regulators of EMT to augment invasiveness
and migration of mammary proliferating epithelial cells (72).
Also, activated STAT3 seems to be crucial for the activation of
CSC maintenance by leptin signaling in triple negative breast
cancer (73). In this line, recent data from human breast-cancer-
studies suggest that leptin-activated STAT3, also promotes cancer
cell stemness and chemoresistance through the expression of
critical enzymes for acid β-oxidation pathways (74).
MAPK Pathway
Phosphorylation on tyrosine 985 recruits SHP2 to the leptin
receptor, contributing to the activation of the MAPK signaling
pathway, which plays an important role in the activation of
ERK 1/2, p38, and JNK (51). They also induce the activation of
HIF-1α and NF-κB, and these transcription factors are linked to
the regulation of VEGF/VEGFR-2 by leptin. In addition, MAPK
induces the phosphorylation and activation of transcription
factors, such as c-jun, c-fos, c-myc, and erg-1, which act in
the nucleus by promoting expression of genes that regulate cell
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FIGURE 3 | Mechanisms of leptin action in breast cancer cells. The cartoon shows the signaling pathways that mediate the leptin effects on breast cancer cells.
proliferation and differentiation. In addition, tyrosine 985 also is
a binding site for SOCS3, playing an essential role in feedback
inhibition of LEPR (75).
The role of leptin promoting growth via ERK pathway has
been demonstrated in breast cancer models (76). In addition, this
molecular pathway has been involved in the functional activation
of the estrogen receptor alpha (ERα) (77, 78) as well as in the
induction of aromatase mediated by leptin in breast tissue (79).
PI3K Pathway
Another protein with SH2 domain, SH2B1, also participates
in LEPR signaling. Apart from increasing LEPR signaling
through JAK2, SH2B1 can control specific signals on the
insulin receptor substrate (IRS). IRS proteins control the PI3K
pathway and the subsequent regulation of Akt signaling [Review
in (80)]. Acting mainly through proteins phosphorylation,
this pathway affects cellular properties more rapidly than
other pathways.
PI3K pathway has been considered an important link between
obesity, leptin and increased risk of breast cancer (31, 81).
Specifically, it has been proposed that PI3K/AKT regulates leptin
mediated-epithelial mesenchymal transition in breast cancer. In
this process, this pathway has been suggested to participate
in IL-8 (82) and pyruvate kinase M2 (PKM2) upregulation
mediated by leptin (83). Furthermore, other recent study has
proposed leptin to enhance the proliferation, migration and
invasion of breast cancer cells via acetyl-CoA acetyltransferase
2 (ACAT2) up-regulation through the PI3K/AKT/SREBP2
signaling pathway (84).
Leptin Crosstalk in Breast Cancer
Leptin has been linked to different stages and processes
related to development and progression of breast cancer,
involving the action of some mediators that participate
in a more complex signaling transduction network.
Thus, leptin functions are commonly reinforced through
crosstalk with multiple oncogenes, cytokines and growth
factors (60).
Leptin signaling enhances tumor formation, proliferation and
invasion by activation of cancer stem cell signaling pathways. In
this sense, leptin seems to participate in the expression of stem
cell self-renewal transcription factors Nanog, SOX2, and OCT4
(63). Additionally, leptin induces canonical Wnt1 signal pathway
functioning through β-catenin-dependent mechanisms. Several
leptin dependent signaling kinases, including ERK-p90-RSK and
Akt, which phosphorylate GSK3β, along with the increase of
MTA1 expression by leptin, regulate the function of this Wnt
pathway to promote epithelial-mesenchymal transition in breast
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cancer cells (85). In addition, leptin-Notch axis seems to play a
role in breast cancer development, as it has been demonstrated in
some models of breast cancer cells. A complex signaling crosstalk
between leptin, Notch and interleukin-1 (IL-1) seems to be an
important driver of leptin-induced oncogenic action (86).
Regarding angiogenesis regulation by leptin in breast cancer,
some studies have shown that the activation of HIF-1α
and NF-κB by leptin are essential in the regulation of
VEGF, which promotes angiogenesis (87). In addition, leptin
participates in the phosphorylation of VEGFR-2 (VEGF type
2 receptor) independently of VEGF in endothelial cells and
breast cancer cells (60). Also the expression of this factor has
been demonstrated to be increased through Notch, IL1, and
leptin crosstalk (88), which could represent the integration of
developmental, proinflammatory and pro-angiogenic signals.
In addition, various studies have integrated leptin and cAMP
signaling pathways in breast cancer, specifically in triple negative
breast cancer (89). Despite the role of cAMP and leptin,
respectively, as growth suppressor and growth promoting factors
in breast cancer cells, an antiproliferative interaction between
leptin and cAMP elevation has been described (90). Thus, cAMP
elevation seems to completely prevent leptin-induced migration
of MDA-MB-231 breast cancer cells (91).
Other receptors have been proposed to be functionally
important mediating the actions of leptin in breast cancer. Leptin
and TGFβ1 seem to promote metastasis and stemness in breast
cancer cells (92). As another example of this point of convergence
with TGFβ signaling, leptin has been involved in metastasis and
recurrence of breast cancer, likely participating in the inhibition
of acetil CoA carboxylase 1 (ACC1) (93). In addition, the
crosstalk between leptin and epidermal growth factor receptor
(EGFR) signaling pathways could alter significantly the behavior
of different cell types in cancer. Thus, it has been described
bidirectional crosstalk between leptin and IGF-1 signaling,
resulting in the activation of EGFR to promote proliferation
and migration of triple negative breast cancer cells (39). An
additional support for the existing link between leptin and other
receptors is the close cooperation that was also demonstrated
between leptin and HER2 (94). Not only HER2 seems to induce
the expression of leptin in human breast epithelial cells (95),
but also leptin can transactivate HER2 through the activation of
the EGFR and the activation of JAK2, resulting in the growth
of cancerous breast cells with overexpression of HER2 (14, 96).
Therefore, the coexpression of HER2 and the leptin/LEPR system
could contribute to increase the activity of HER2, reducing the
sensitivity to monoclonal trastuzumab treatments for this type of
breast cancer (29).
Leptin and Estrogens
Estrogens play an important role in breast cancer, probably
by stimulating cellular proliferation and oxidative metabolism
mediated by various cytochrome P450 (CYP) enzymes such as
CYP1A1 and CYP1B1. In breast tissues, the main estrogen, 17β-
oestradiol (E2), is a ligand for the estrogen receptor α (ERα) and
a substrate for the phase I enzyme cytochrome P450 CYP1B1. A
large body of evidence has established the fundamental role of
E2 and its receptor in the development and progression of breast
cancer (97).
Leptin specifically enhances tumorigenicity of estrogen
positive breast cancer cells (98). A bidirectional communication
between LEPR and ERα was suggested by the statistically
significant correlation between the expression of both receptors
in breast cancer cells lines and ex vivo studies (99). Leptin has
been suggested to induce CYP1B1 expression in ERα-positive
breast cancer cells in a mechanism that involves AKT and ERK
signaling pathways (78). Moreover, it has been demonstrated
that leptin from adipose stromal/stem cells induces a differential
pattern of gene expression in ERα-positive compared to negative
breast cancer cells (100).
Leptin also exerts its effects by increasing cell viability
and proliferation through crosstalk with estrogen receptor-
alpha (ERα). Both STAT3 activation and ERK1/ERK2 signaling
mediated by leptin have been described to act as a key event in
ERα-dependent development of breast cancer (77, 101). Recently,
a novel mechanism has been proposed for the role of leptin
in breast cancer progression in ER-α positive cells. It involves
JAK/STAT3-Akt signaling pathways in the suppression of the
extracellular matrix protein CCN5, which acts as an anti-invasive
element in cancer (102). Other studies have demonstrated that
estrogen receptor signaling plays a key role in leptin-induced
growth of breast cancer cells via autophagy activation (103).
An additional functional relation between leptin and estrogen
signaling has been suggested based on the estrogen receptors
status and the aromatase activity. In this sense, leptin promotes
the synthesis of estrogen, which is related to an increased risk
of breast cancer. Leptin was demonstrated to enhance aromatase
expression in MCF7 cells (104) and this cytokine with some
other inflammatory mediators are key stimulators of aromatase
transcript expression also in adipose stromal breast cells (105).
Some mechanisms have been proposed for the effect of
leptin on the aromatase expression. A positive association
between leptin expression, LEPR, aromatase and MAPK and
STAT3 activation has been suggested using tissue samples of
patients with estrogen receptor positive breast cancer (106).
Apart from that, PGE2 and leptin have been shown to drive
aromatase expression via the suppression of the metabolic
regulators LKB1/AMPK (107). Additionally, the increase in
leptin-dependent aromatase expression has been correlated with
COX-2 upregulation and cooperation among multiple signaling
pathways (108). Specifically, a novel mechanism has been
proposed based on leptin-dependent PKC/MAPK signaling, the
suppression of p53, and HIF1α and PKM2 as direct mediators of
aromatase expression (79).
Leptin and Therapeutic Targets in Breast
Cancer
Leptin network relationships have been correlated to prognosis
and also pharmacological responses in some follow-up studies
of breast cancer. For instance, patients with breast cancer who
have high levels of leptin but with negative expression of estrogen
hormone receptor have a higher survival rate. Therefore, a
positive leptin/negative hormone receptor status is indicative of
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good response to chemotherapy and prognosis, whereas those
with a positive leptin/positive hormone receptor profile have
a poor response (22). Additionally, it has been demonstrated
that leptin interferes with the action of tamoxifen under beta-
estradiol stimulated conditions in ER-positive breast cancer cells
(109, 110). Accounting for the role of obesity and leptin in
breast cancer, several possible mechanisms have been suggested
to potentially mediate drug resistance in tumor cells (111).
Different proposed therapeutic strategies for breast cancer
treatment include the use of soluble leptin receptors, peptide-
based leptin antagonists and leptin receptor blocking antibodies
(45). Apart from this, events that promote leptin negative
regulation are emerging as novel therapeutic targets for patients
with breast cancer. The anti-leptin activity of 1,25(OH)2D3
in estrogen-sensitive tumors in women seems to mediate
telomerase reverse transcriptase (hTERT) downregulation (112).
Also, PPARγ ligands are demonstrated to inhibit leptin signaling
mediated by MAPK/STAT3/Akt phosphorylation and counteract
leptin stimulatory effect on estrogen signaling. Thus, PPARγ
ligands have been suggested as therapeutic molecules for breast
cancer treatment (113).
THE PARADOX OF THE BENEFITS OF
OBESITY IN CANCER
On the other hand, even though the association between obesity,
inflammation, and many different types of cancer is clear (114),
some controversial data still remains, including breast cancer,
where the dialog between the adipocyte and the breast cancer
cells is well-known to potentiate not only the growth or invasion,
but also treatment resistance (115). Thus, old and new data have
also shown that moderately increased BMI improves the survival
and response to therapy. However, this effect is lost when BMI
increases to morbid obesity levels, leading to the concept of
“obesity paradox” (116). This paradox is similar to that observed
in other pathological conditions, such as cardiovascular disease
(117). Although the obesity paradox in cancer is less studied, it
has been related to the inadequate use of BMI for the overweight,
since protective muscle mass may also contribute to BMI (118).
Besides, weight depend on the stage of the disease, since cancer
produces weight loss, and the time of measurement different
studies may be misleading. Moreover, the excess of adipose tissue
may represent an energy store that warrants further surviving
time in some patients.
We think that both ideas may be conciliated, since chronic
inflammation due to obesity may lead to cancer, whereas very
low BMI may produce some immunodeficient state that favor
the immune scape of cancer cells. On the other hand, once
the cancer has been diagnosed, regardless the main cause
of the tumor (tobacco, UV-radiation. . . ), the proinflammatory
state of the obese subject may be helpful for the immune
response against the tumor. Finally, the increased fat stores
may provide an energy reserve that may be useful for a longer
survival time.
The Beneficial Effect of Obesity in the
Tumor Response to Immunotherapy
Immunotherapy has revolutionized cancer therapy in the last 10
years (119) and is now one of the cornerstone of both adjuvant
and neoadjuvant therapies, alone or in combination with other
chemotherapy or radiotherapy treatment (120, 121). In this
line, immunotherapy has opened new horizons in breast cancer
(122). Recent data has shown the beneficial effect of obesity
in the efficacy of immunotherapy (123). Thus, cancer patients
with overweight or obesity (BMI > 25) have shown to have
a better response to treatment with anti-PD1/PD-L1 immune
checkpoint inhibitors (124). This beneficial effect of increased
BMI has been demonstrated in obese patients with metastatic
melanoma (125, 126), where a mechanism mediated by chronic
inflammation and increased C-reactive protein concentration has
been proposed (127).Whether leptin contributes to this favorable
effect of overweight on the response to immunotherapy warrants
further investigation (128). Therefore, the association of obesity
and the increased leptin levels with the response to treatment
should be also investigated in breast cancer patients to better
understand the response to immunotherapy as well as the better
control of the appearance of side effects (Figure 2).
CONCLUSIONS
Obesity is a known risk factor for the developing of breast cancer
in post-menopausal women. The molecular mechanisms
underlying the relationship between obesity and breast
carcinogenesis involves estrogens, insulin, leptin, adiponectin,
and inflammatory cytokines. Specifically, the activation of
leptin signaling results in concurrent activation of multiple
oncogenic pathways leading to an increased proliferation,
epithelial-mesenchymal transition, migration and invasion of
breast cancer cells. In this context, the knowledge of the complex
molecular network of leptin signaling responsible for mammary
carcinogenesis may provide novel ideas for the prevention
and treatment of breast cancer associated to obesity. On the
other hand, obesity has recently been found to be favorable
for the response to immune checkpoint inhibitors in different
tumors, even though this effect remains to be studied in breast
cancer. Therefore, the role of leptin, and other adipokines on
immunological response in cancer therapy should be considered
in future studies.
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